目的 探討甲潑尼龍聯(lián)合阿奇霉素治療小兒肺炎支原體大葉性肺炎的臨床效果。方法 將西安市中心醫(yī)院自2014年1月-2016年12月收治的肺炎支原體大葉性肺炎患兒122例作為研究對象，隨機分為研究組和對照組各61例，患兒入院后給予相應的對癥治療，其中對照組給予阿奇霉素進行治療，研究組患兒在對照組治療的基礎上聯(lián)合甲潑尼龍進行治療，觀察兩組患兒的臨床療效。結果 治療前兩組患兒C反應蛋白（CRP）指標比較差異不大，治療后均明顯降低，其中研究組患兒降低程度顯著優(yōu)于對照組，研究組患兒體溫恢復時間和住院時間均顯著少于對照組，差異具有統(tǒng)計學意義（P < 0.05）。研究組患兒臨床總有效率為98.59%，顯著高于對照組84.85%，組間比較差異具有統(tǒng)計學意義（P < 0.05）。兩組均未發(fā)生嚴重不良反應。結論 甲潑尼龍聯(lián)合阿奇霉素治療小兒肺炎支原體大葉性肺炎能夠較好的緩解癥狀，降低CRP水平，效果顯著，安全有效，可推廣使用。

Objective To investigate the clinical effect of azithromycin combined with methylprednisolone in the treatment of mycoplasma pneumoniae. Methods A total of 122 children with mycoplasma pneumoniae pneumonia were enrolled in our hospital from January 2014 to December 2016. They were randomly divided into study group and control group (61 cases). The corresponding symptomatic treatment, which control the oral administration of azithromycin treatment, the study group of children in the control group based on the treatment of methylprednisolone treatment, to observe the clinical efficacy of the two groups of children. Results There was no significant difference in CRP between the two groups before treatment, and the levels of CRP in the study group were significantly lower than those in the control group. The recovery time and hospitalization time of the study group were significantly lower than those of the control group, The total effective rate was 98.59% in the study group, which was significantly higher than that in the control group (84.85%). There was significant difference between the two groups (P < 0.05). There had no serve adverse reactions in two groups. Conclusion Azithromycin combined with methylprednisolone can reduce the level of CRP in children with mycoplasma pneumoniae, which can alleviate the symptoms and reduce the level of CRP. The effect is remarkable and can be popularized.